Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-13

Clinical Trial Update: A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of gantenerumab in prodromal Alzheimer's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gantenerumab (gantenerumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-12-13